Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets
There is accumulating evidence for potential benefits of therapeutic drug monitoring (TDM)
in the treatment of cancer with tyrosine kinase inhibitors (TKIs). Relationships between …
in the treatment of cancer with tyrosine kinase inhibitors (TKIs). Relationships between …
Skin toxicities associated with epidermal growth factor receptor inhibitors
T Li, R Perez-Soler - Targeted oncology, 2009 - Springer
The use of epidermal growth factor receptor (EGFR) inhibitors in several epithelial tumors
has increased considerably in recent years. Currently, they are approved in non-small cell …
has increased considerably in recent years. Currently, they are approved in non-small cell …
A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck
CM Lewis, BS Glisson, L Feng, F Wan, X Tang… - Clinical Cancer …, 2012 - AACR
Purpose: To determine the disease control rate and toxicity of treating patients with
aggressive cutaneous squamous cell carcinoma (CSCC) with neoadjuvant gefitinib …
aggressive cutaneous squamous cell carcinoma (CSCC) with neoadjuvant gefitinib …
Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas
ContextMalignancies arising from the aerodigestive epithelium, including lung, head and
neck, and esophageal carcinomas, are the leading causes of cancer-related mortality …
neck, and esophageal carcinomas, are the leading causes of cancer-related mortality …
Individualized dosing of tyrosine kinase inhibitors: are we there yet?
D de Wit, HJ Guchelaar, J den Hartigh… - Drug discovery today, 2015 - Elsevier
Highlights•Complete overview on exposure–response relationships for TKIs used in solid
tumors.•Dose individualization is expected to minimize toxicity and improve efficacy.•For …
tumors.•Dose individualization is expected to minimize toxicity and improve efficacy.•For …
Nerve growth factor (NGF)-TrkA axis in head and neck squamous cell carcinoma triggers EMT and confers resistance to the EGFR inhibitor erlotinib
C Lin, Z Ren, XI Yang, R Yang, Y Chen, Z Liu, Z Dai… - Cancer letters, 2020 - Elsevier
Understanding the molecular mechanisms regulating tumor dissemination and therapeutic
resistance is of central importance for effective cancer therapies. Here, we report that nerve …
resistance is of central importance for effective cancer therapies. Here, we report that nerve …
NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme
DM Peereboom, MS Ahluwalia, X Ye, JG Supko… - Neuro …, 2013 - academic.oup.com
Background The signal transduction pathways of epidermal growth factor receptor and Ras
are both important in the growth of glioblastoma multiforme (GBM). We hypothesized that …
are both important in the growth of glioblastoma multiforme (GBM). We hypothesized that …
A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients
E Messing, JR Gee, DR Saltzstein, KM Kim… - Cancer prevention …, 2012 - AACR
The soy compound genistein has been observed preclinically to inhibit bladder cancer
growth with one potential mechanism being the inhibition of epidermal growth factor …
growth with one potential mechanism being the inhibition of epidermal growth factor …
Targeting EGFR resistance networks in head and neck cancer
V Ratushny, I Astsaturov, BA Burtness, EA Golemis… - Cellular signalling, 2009 - Elsevier
A core set of oncoproteins is overexpressed or functionally activated in many types of
cancer, and members of this group have attracted significant interest as subjects for …
cancer, and members of this group have attracted significant interest as subjects for …
Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure
Introduction: Small molecule protein kinase inhibitors (KIs) are a class of drugs with complex
and unconventional physiochemical and pharmacokinetic characteristics. Cytochrome P450 …
and unconventional physiochemical and pharmacokinetic characteristics. Cytochrome P450 …